Researchers have conducted that the largest detailed published study of people with a poorly understood skin condition known as prurigo nodularis (PN). Such studies collect information on a whole subset of people at once and at a particular point in time. Prurigo Nodularis (PN) is a poorly understood, understudied pruritic dermatosis that reduces the quality of life. The study was published in the Journal of the American Academy of Dermatology.
Their results provide some of the first published reliable information from a racially diverse population about who likely develops this chronic disease, which is characterized by intensely itchy nodules that develop on the arms and legs that can generalize throughout the body.
Prevalence Of PN
The prevalence of PN remains unknown as the condition has been understudied compared with other inflammatory skin diseases, and its origins, causes, and treatment are still largely unexplored. These are patients whose lives have been devastated by an unbearable, persistent itch that dramatically reduces the quality of life on par with the most severe diseases treated by our specialty.
Besides the immense discomfort from itching and scratching, PN interferes with sleep and affects social interactions with people who may be (needlessly) afraid of contracting this noninfectious disease. Despite its severe impact, he adds, PN has been largely ignored by scientists.
To learn more about it, they conducted a detailed study of data from 909 adults with PN over a five-year period. There were 475 females and 434 males. Of the participants, nearly half were African American, about 42% were white, and about 3% were Asian.
The majority of patients, nearly half, were between 51 and 65 years old. The findings also suggest that the condition disproportionately affects African-Americans between ages 50 and 65 as compared with the general population.
PN was more prevalent in African-Americans, but not whites, with HIV infection. African-Americans with PN in the patient group were 10.5 times more likely to have HIV than race-matched controls with atopic dermatitis and eight times more likely to have HIV than African-American patients with psoriasis who were treated during this period.
PN patients were also 2.8, 4.7 and 9.9 times more likely to have diabetes, chronic kidney disease, and hepatitis C than patients with atopic dermatitis, respectively. Further, patients with PN were nearly three times more likely to have clinical depression compared with patients with atopic dermatitis and 2.4 times more likely to have depression than patients with psoriasis.
The team suggests their information may be used not only in the clinical care of PN patients but forms a basis for ongoing translational studies to develop novel treatments for the disorder, which has no FDA-approved therapy or consistently effective treatment. The connections between PN and various health conditions could lead physicians to give patients more thorough evaluations to check for other conditions once they're diagnosed with PN.
Current systemic treatments for PN include phototherapy, neuroactive agents such as gabapentin and pregabalin, and systemic immunosuppressants such as methotrexate and cyclosporine. As PN is associated with dermatologic conditions such as atopic dermatitis in African-Americans, as well as many systemic conditions, further study is needed to determine the exact prevalence.
PN disproportionately affects African-Americans and is associated with several systemic conditions including HIV, chronic kidney disease, and diabetes.